Pyxis Oncology, Inc. Investment Income, Interest
Pyxis Oncology, Inc. (PYXS) reported Investment Income, Interest of $61.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-13
- Pyxis Oncology, Inc. investment income, interest for the quarter ending 2026-06-30 was $61.00K, a 38.38% decline year-over-year.
- Pyxis Oncology, Inc. investment income, interest for the quarter ending 2026-03-31 was $218.00K, a 159.52% increase year-over-year.
- Pyxis Oncology, Inc. investment income, interest for the quarter ending 2025-12-31 was $225.00K, a 158.62% increase year-over-year.
- Pyxis Oncology, Inc. investment income, interest for the quarter ending 2025-09-30 was $242.00K, a 24.74% increase year-over-year.
- Pyxis Oncology, Inc. investment income, interest for fiscal 2025 was $650.00K, a 30.11% decline from fiscal 2024.
- Pyxis Oncology, Inc. investment income, interest for fiscal 2024 was $930.00K, a 49.51% decline from fiscal 2023.
- Pyxis Oncology, Inc. investment income, interest for fiscal 2023 was $1.84M, a 33.36% decline from fiscal 2022.
- Pyxis Oncology, Inc. investment income, interest for fiscal 2022 was $2.76M, a 11917.39% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $61.00K 10-Q · filed 2026-08-13 | $279.00K 10-Q · filed 2026-08-13 | $504.00K derived: sum of 3 quarters · filed 2026-08-13 | $746.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $218.00K 10-Q · filed 2026-05-14 | $443.00K derived: sum of 2 quarters · filed 2026-05-14 | $685.00K derived: sum of 3 quarters · filed 2026-05-14 | $784.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $225.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $467.00K derived: sum of 2 quarters · filed 2026-03-23 | $566.00K derived: sum of 3 quarters · filed 2026-08-13 | $650.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $242.00K 10-Q · filed 2025-11-03 | $341.00K derived: sum of 2 quarters · filed 2026-08-13 | $425.00K 10-Q · filed 2025-11-03 | $512.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $99.00K 10-Q · filed 2026-08-13 | $183.00K 10-Q · filed 2026-08-13 | $270.00K derived: sum of 3 quarters · filed 2026-08-13 | $464.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $84.00K 10-Q · filed 2026-05-14 | $171.00K derived: sum of 2 quarters · filed 2026-05-14 | $365.00K derived: sum of 3 quarters · filed 2026-05-14 | $752.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $281.00K derived: sum of 2 quarters · filed 2026-03-23 | $668.00K derived: sum of 3 quarters · filed 2026-03-23 | $930.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $194.00K 10-Q · filed 2025-11-03 | $581.00K derived: sum of 2 quarters · filed 2025-11-03 | $843.00K 10-Q · filed 2025-11-03 | $996.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $387.00K 10-Q · filed 2025-08-14 | $649.00K 10-Q · filed 2025-08-14 | $802.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.03M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $262.00K 10-Q · filed 2025-05-15 | $415.00K derived: sum of 2 quarters · filed 2025-05-15 | $642.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.04M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $380.00K derived: sum of 2 quarters · filed 2025-03-18 | $776.00K derived: sum of 3 quarters · filed 2025-03-18 | $1.84M 10-K · filed 2025-03-18 |
| 2023-09-30 | $227.00K 10-Q · filed 2024-11-12 | $623.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.69M 10-Q · filed 2024-11-12 | $3.56M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $396.00K 10-Q · filed 2024-08-14 | $1.46M 10-Q · filed 2024-08-14 | $3.33M derived: sum of 3 quarters · filed 2024-08-14 | $4.05M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $1.07M 10-Q · filed 2024-05-14 | $2.94M derived: sum of 2 quarters · filed 2024-05-14 | $3.66M derived: sum of 3 quarters · filed 2024-05-14 | $3.82M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.59M derived: sum of 2 quarters · filed 2024-03-21 | $2.75M derived: sum of 3 quarters · filed 2024-03-21 | $2.76M 10-K · filed 2024-03-21 |
| 2022-09-30 | $719.00K 10-Q · filed 2023-11-07 | $883.00K derived: sum of 2 quarters · filed 2023-11-07 | $892.00K 10-Q · filed 2023-11-07 | $899.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $164.00K 10-Q · filed 2023-08-11 | $173.00K 10-Q · filed 2023-08-11 | $180.00K derived: sum of 3 quarters · filed 2023-08-11 | $186.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $9.00K 10-Q · filed 2023-05-11 | $16.00K derived: sum of 2 quarters · filed 2023-05-11 | $22.00K derived: sum of 3 quarters · filed 2023-05-11 | $28.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $13.00K derived: sum of 2 quarters · filed 2023-03-22 | $19.00K derived: sum of 3 quarters · filed 2023-03-22 | $23.00K 10-K · filed 2023-03-22 |
| 2021-09-30 | $6.00K 10-Q · filed 2022-11-01 | $12.00K derived: sum of 2 quarters · filed 2022-11-01 | $16.00K 10-Q · filed 2022-11-01 | $16.00K derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $6.00K 10-Q · filed 2022-08-15 | $10.00K 10-Q · filed 2022-08-15 | $10.00K derived: sum of 3 quarters · filed 2022-08-15 | $11.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $4.00K 10-Q · filed 2022-05-13 | $4.00K derived: sum of 2 quarters · filed 2022-05-13 | $5.00K derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.00K derived: sum of 2 quarters · filed 2022-03-29 | $66.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-15 | $66.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |